http://www.urowiki.or.kr/wiki/index.php?action=history&feed=atom&title=%EC%A0%84%EB%A6%BD%EC%84%A0%EC%95%94_%EA%B3%A8%EC%A0%84%EC%9D%B4_%27%EC%97%91%EC%8A%A4%EC%A7%80%EB%B0%94%27%EC%A3%BC%EC%82%AC%EC%A0%9C_%EA%B8%89%EC%97%AC_%EC%8B%A0%EC%84%A4_%EC%95%88%EB%82%B4 2026-05-06T03:07:22Z 이 문서의 편집 역사 MediaWiki 1.35.11 http://www.urowiki.or.kr/wiki/index.php?title=%EC%A0%84%EB%A6%BD%EC%84%A0%EC%95%94_%EA%B3%A8%EC%A0%84%EC%9D%B4_%27%EC%97%91%EC%8A%A4%EC%A7%80%EB%B0%94%27%EC%A3%BC%EC%82%AC%EC%A0%9C_%EA%B8%89%EC%97%AC_%EC%8B%A0%EC%84%A4_%EC%95%88%EB%82%B4&diff=3902&oldid=prev 2019-10-10T00:12:56Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="ko"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← 이전 판</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2019년 10월 10일 (목) 00:12 판</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >1번째 줄:</td> <td colspan="2" class="diff-lineno">1번째 줄:</td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>-</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">=== 전립선암 골전이 치료제 ‘denosumab’ 주사제(품명: 엑스지바주)에 대한 급여 안내 ===</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">2018년 9월 1일부터 전립선암 골전이에 사용하는 ‘denosumab’ 주사제(품명: 엑스지바주)가 급여 인정되었기에 다음과 같이 안내드립니다. 급여기준을 확인하시어 환자진료에 많은 도움이 되시기를 바랍니다. </ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">관련 근거 :건강보험심사평가원 공고 제2018</ins>-<ins class="diffchange diffchange-inline">210호(2018. 8. 30)</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">‘암환에게 처방·투여하는 약제에 대한 요양급여의 적용기준 및 방법에 관한 세부사항’중 'denosumab’ 관련 급여기준 개정사항 안내</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">[주요개정내역]</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">○ 기타 약제에 ‘denosumab’ 주사제(품명: 엑스지바주)</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">만 19세 이상 유방암, 전립선암의 골전이에 아래와 같은 기준으로 투여하는 경우에 인정함. </ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">-  아    래  -</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">(1) 투여조건</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">'''단순 방사선 검사(plain X-ray) 상 lytic 소견을 보이는 경우, 또는 X-ray 상 정상이나 CT 또는 MRI로 골파괴가 명확히 입증된 경우에 인정함. 단, bone scan만으로 이상 소견이 확인된 경우는 인정하지 아니함'''</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">(2) 암종별 적용기준</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">'''○ 전립선암: 허가사항 범위 내에서 필요ㆍ적절하게 투여 시 인정함'''</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">※ 허가사항 범위이지만 상기 인정기준 이외에 투여하는 경우의 비용부담은 보건복지부 고시에 따라 약값 전액을 본인이 부담토록 함 </ins></div></td></tr> </table>

Sjlee http://www.urowiki.or.kr/wiki/index.php?title=%EC%A0%84%EB%A6%BD%EC%84%A0%EC%95%94_%EA%B3%A8%EC%A0%84%EC%9D%B4_%27%EC%97%91%EC%8A%A4%EC%A7%80%EB%B0%94%27%EC%A3%BC%EC%82%AC%EC%A0%9C_%EA%B8%89%EC%97%AC_%EC%8B%A0%EC%84%A4_%EC%95%88%EB%82%B4&diff=3875&oldid=prev 2019-10-10T00:05:19Z

<p>새 문서: -</p> <p><b>새 문서</b></p><div>-</div>

Sjlee